Literature DB >> 7955631

Juvenile dermatomyositis (JDMS): new clues to diagnosis and pathogenesis.

L M Pachman1.   

Abstract

The localization of focal inflammatory myopathy (IM) is aided by MRI, which facilitates diagnostic testing (muscle biopsy or EMG). Antibodies to antigens involved in protein synthesis are specific for IM and characterize distinct subsets of adult IM, but are rare in pediatric IM. In definite juvenile dermatomyositis, serological indicators of disease activity include neopterin and von Willebrand factor antigen, markers of macrophage activation, and endothelial cell damage, respectively; nailfold capillarioscopy documents small blood vessel involvement. Monitoring the percentage of circulating B cells may indicate the response to therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7955631

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  4 in total

1.  Juvenile dermatomyositis.

Authors:  V Seth; S K Kabra; O P Semwal; Y Jain
Journal:  Indian J Pediatr       Date:  1996 May-Jun       Impact factor: 1.967

2.  Inflammatory myopathy, bronchiolitis obliterans/organizing pneumonia, and anti-Jo-1 antibodies--an interesting association.

Authors:  M Kalenian; B Zweiman
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

3.  Mycophenolate mofetil in juvenile dermatomyositis: a case series.

Authors:  Rawane Dagher; Marine Desjonquères; Agnès Duquesne; Pierre Quartier; Brigitte Bader-Meunier; Michel Fischbach; Vincent Guiguonis; Georges Picherot; Rolando Cimaz
Journal:  Rheumatol Int       Date:  2010-12-09       Impact factor: 2.631

4.  Oligoclonal expansion of circulating and tissue-infiltrating CD8+ T cells with killer/effector phenotypes in juvenile dermatomyositis syndrome.

Authors:  K Mizuno; A Yachie; S Nagaoki; H Wada; K Okada; M Kawachi; T Toma; A Konno; K Ohta; Y Kasahara; S Koizumi
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.